Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Lancet neurology Ročník 16; číslo 4; s. 271 - 281
Hlavní autori:	Kalincik, Tomas, Brown, J William L, Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M, Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent, Rozsa, Csilla, Grand'Maison, François, Boz, Cavit, Granella, Franco, Slee, Mark, Spitaleri, Daniele, Olascoaga, Javier, Bergamaschi, Roberto, Verheul, Freek, Vucic, Steve, McCombe, Pamela, Hodgkinson, Suzanne, Sanchez-Menoyo, Jose Luis, Ampapa, Radek, Simo, Magdolna, Csepany, Tunde, Ramo, Cristina, Cristiano, Edgardo, Barnett, Michael, Butzkueven, Helmut, Coles, Alasdair
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.04.2017 Elsevier Limited
Predmet:	Adult Alemtuzumab Antibodies, Monoclonal, Humanized - therapeutic use Clinical medicine Clinical trials Cohort Studies Data entry Databases, Bibliographic - statistics & numerical data Disability Evaluation Female Fingolimod Hydrochloride - therapeutic use Humans Immunologic Factors - therapeutic use Immunotherapy Interferon Interferon-beta - therapeutic use Male Medical research Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurology Pharmaceutical industry Quality Studies Treatment Outcome Young Adult
ISSN:	1474-4422, 1474-4465, 1474-4465
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!